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Abstract
We present a case of MEN 2B diagnosed in a 23 year-old patient on the basis of bilateral pheochromocytoma and medullary thyroid carci-
noma. This young male patient also had multiple paragangliomas located along the spine, marfanoid features of body habitus and numerous 
mucosal neuromas of the oral cavity and intestinal ganglioneuromatosis. The patient was hospitalised several times between the ages of 11 
and 14 due to heart rhythm disorders (tachycardia, multiple supraventricular beats) and pain in the precardiac area. Elevated blood pressure 
was not observed at that time. In 2010, the patient was admitted to hospital due to abdominal pain, nausea, vomiting and hypertension; 
bilateral adrenal tumours were then detected. The patient was referred to the Department of Endocrinology in Szczecin, with suspected 
pheochromocytoma in order to continue the diagnostic process. This resulted in the diagnosis of bilateral pheochromocytoma and medul-
lary thyroid carcinoma. On the basis of the whole clinical picture, the diagnosis of MEN 2B was established and subsequently confirmed 
with genetic test results. Following the removal of adrenal tumours and thyroidectomy, the patient was referred to the Cancer Centre 
and Institute of Oncology in Gliwice for further treatment (X-ray therapy and further surgery due to recurrence of medullary carcinoma).
This article presents a case of late MEN 2B diagnosis despite the presence of clinical symptoms suggestive of Multiple Endocrine Neoplasia 
observed from early childhood. (Pol J Endocrinol 2011; 62 (6): 548–553)
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Streszczenie
W pracy przedstawiono przypadek zespołu MEN 2B u 23-letniego pacjenta na podstawie obecności obustronnych guzów chromochłon-
nych nadnerczy oraz raka rdzeniastego tarczycy. U młodego mężczyzny stwierdzono ponadto mnogie przyzwojaki przykręgosłupowe, 
marfanoidalną budowę ciała oraz liczne włókniaki błon śluzowych jamy ustnej i przewodu pokarmowego. Pacjent był kilkakrotnie hospi-
talizowany w wieku 11–14 lat z powodu zaburzeń rytmu serca (tachykardii, licznych pobudzeń nadkomorowych) oraz bólów w okolicy 
przedsercowej. W tym okresie nie obserwowano podwyższonych wartości ciśnienia tętniczego. W 2010 roku chorego hospitalizowano 
z powodu bólów brzucha, nudności, wymiotów oraz nadciśnienia tętniczego, rozpoznano wówczas obustronne guzy nadnerczy. Chorego 
skierowano do dalszej diagnostyki z podejrzeniem pheochromocytoma do Kliniki Endokrynologii w Szczecinie, gdzie potwierdzono diagnozę 
obustronnych guzów chromochłonnych oraz dodatkowo rozpoznano raka rdzeniastego tarczycy. Na podstawie całości obrazu klinicznego 
postawiono rozpoznanie zespołu MEN 2B, potwierdzone w późniejszym okresie badaniem genetycznym. Pacjenta po usunięciu guzów 
nadnerczy oraz po tyroidektomii przekazano do dalszego leczenia (radioterapii i ponownego leczenia chirurgicznego z powodu wznowy 
raka rdzeniastego) do Centrum Onkologii w Gliwicach. 
Celem pracy było przedstawienie przypadku późnego rozpoznania zespołu MEN typu 2B mimo występowania od wczesnego dzieciństwa 
objawów klinicznych mogących sugerować to rozpoznanie. (Endokrynol Pol 2011; 62 (6): 548–553)
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Introduction
Type 2B multiple endocrine neoplasia (MEN 2B) is a rare 
congenital syndrome associated with hyperplasia and 
neoplasia affecting the thyroid gland, adrenal medulla 
as well as nervous and connective tissues. MEN 2B is 
characterised by the development of medullary thyroid 
carcinoma (90%), uni- or bilateral pheochromocytoma 
(45–50%), marfanoid body habitus (65–75%) and other 
hyperplastic lesions such as neuromas of the tongue 
and mucous membrane, typically of lips, cheeks, tonsils 
and eye-lids as well as thickening of the corneal nerve 
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observed during examination with a slit lamp. Skeletal 
anomalies have also been reported, including kypho-
scoliosis, lordosis, feet and femoral bone deformation 
and dislocation of joints [1, 2]. 
Medullary thyroid carcinoma originating from para-
follicular cells (C-cells) producing calcitonin, associated 
with MEN 2B is very aggressive and has a poor prog-
nosis [3]. Therefore, in early-diagnosed genetic MEN 
2B, preventative removal of the thyroid gland as early 
as the first year of life is recommended. Cases of med-
ullary thyroid carcinoma of 5 mm have been reported 
in 17 month-old children [4]. MEN 2B represents less 
than 10% of MEN 2 syndromes, and is associated with 
a higher mortality rate than MEN 2A [5]. 
Catecholamine-producing pheochromocytoma oc-
curs in around 50% of MEN 2B cases, and is the first 
sign of the disease in around 25% of cases. Medul-
lary carcinoma is the first sign of MEN 2B in 40% of 
cases. Pheochromocytoma is usually benign, and its 
bilateral occurrence is reported in 50–80% of cases [6, 7]. 
Case study
A 23 year-old male patient was referred to the Depart-
ment of Endocrinology in Szczecin with suspected 
pheochromocytoma. Having analysed his medical 
history, we found that the clinical symptoms of MEN 
2B had been present since early childhood. The patient 
was born with an orthopaedic anomaly affecting both 
feet, which was diagnosed at that time as bilateral 
inborn peroneal nerve paralysis with talipes equinova-
rus. Consequently, orthopaedic treatment was started 
when the patient was 11 months old. The boy began 
to walk unaided at the age of three. When he was still 
an infant, he suffered from severe constipation requir-
ing additional treatment. In his second year of life, he 
presented considerable weight deficit (body weight 
below the 3rd percentile until the age of 18). At that 
time he also had diarrhoea. The boy was diagnosed for 
possible malabsorption syndrome. Between the ages of 
11 and 14, he was admitted to hospital several times due 
to pain in the precardiac area, palpitation, dyspnoea 
and fainting. He was exempt from PE classes in school 
because of problems with his legs, but every physical 
exercise was poorly tolerated: the boy had palpitation, 
shortness of breath and general weakness. Blood pres-
sure, measured many times on such occasions, yielded 
normal results. 
In 2006, the patient suffered from subcapsular rup-
ture of the spleen as a result of an injury. Ultrasound 
examination of the abdomen performed at that time was 
difficult due to large amounts of fluid in the peritoneal 
cavity and consequently only showed spleen enlarge-
ment and intestinal foci of unclear aetiology. The rup-
tured spleen was removed during laparotomy, together 
with two tumours with diameters of 25 mm and 30 mm. 
Histopathologic examination of these tumours revealed 
the presence of fibrous tissue. The diagnostic process 
was discontinued at this stage. Postoperatively, the 
patient suffered from retrosternal pain and tachycardia 
up to 110 bpm. Apart from tachycardia, ECG findings 
included ST segment elevation in precardiac leads V2 to 
V4, which resolved spontaneously several hours later. 
Blood pressure values during surgery, as well as in the 
perioperative period, were normal.
In January 2010, the patient was admitted to the 
regional hospital unit of internal medicine due to 
chest pain which has been increasing for ten days 
before admission, severe headache, dizziness, nausea, 
vomiting and blood pressure up to 220/130 mm Hg. 
CT of the abdomen performed during hospitalisation 
showed bilateral tumours in the projection of adrenal 
glands, with a tumour diameter of 65 mm. There were 
also other smaller tumours of a diameter not exceeding 
20 mm located at various levels on both sides of the 
spine close to intervertebral foramens, and most likely 
originating from the ganglia. The patient was referred 
to Pomeranian Medical University’s Department of 
Endocrinology  in Szczecin for continuation of the 
diagnostic process and treatment.
Anomalies observed on the day of admission to 
hospital included marfanoid body habitus (leptosomic 
body type, height 176 cm, weight 50 kg, BMI 16.1 kg/m2, 
high-arched palate, loose joints and elastopathy, long, 
thin arms and legs (armspan of 177 cm), flat abducted 
feet, multiple neuromas of mucous membrane and 
tongue, slight asymmetric enlargement of left thyroid 
lobe, silent systolic apex murmur, blood pressure 
140/90 mm Hg despite antihypertensive treatment 
(metoprololol 50 mg, doxazosin 4 mg, amlodipine 
10 mg) (Figure 1). Laboratory findings included throm-
bocythemia, hyperuricaemia (9.22 mg/dl) and hyper-
glycaemia both in fasting condition and in half-daily 
profile (up to 185 mg/dl). OGTT after two hours 
yielded normal blood glucose results. High levels of 
metanephrines and vanillyl mandelic acid (VAM) were 
observed in 24-hour urine output and elevated serum 
levels of chromogranin A, calcitonin, carcinoembrionic 
antigen (CEA) and slightly elevated levels of cortisol and 
ACTH were detected (Table I). Ultrasound examination 
of the thyroid gland revealed a hypoechogenic focal 
lesion with microcalcifications. The lesion measured 
9.7 × 8.5 × 19 mm in the right lobe and a similar lesion 
measuring 15.7 × 11 × 35 mm was located in the left 
lobe (Figure 2). Additionally, ultrasound examination 
revealed enlargement and blurred structure of lymph 
nodes located bilaterally along the sternocleidomastoid 
muscles (Figure 3). I-131 MIBG scintigraphy showed two 
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Figure 1. Marfanoid body habitus and neuromas of cheeks and tongue in a patient with MEN 2B
Rycina 1. Cechy marfanoidalne budowy ciała oraz nerwiakowłókniaki błon śluzowych policzków i języka u pacjenta z zespołem 
MEN 2B
Table I. Hormone levels and tumour markers in a patient with MEN 2B before treatment and after the removal of 
pheochromocytoma and complete removal of the thyroid gland
Tabela I. Stężenia hormonów oraz markerów nowotworowych przed leczeniem oraz po usunięciu guzów nadnerczy 
i po usunięciu tarczycy u pacjenta z zespołem MEN 2B
Hormones and tumour 
markers
Before treatment Pheochromocytoma 
resection 
(one month after)
Thyroid 
resection
(six months after)
Normal range
Unit
Chromogranin A 2,034.0 370.0 425 20–150 ng/ml
Metanephrines 986.0 42.0 94.5 25–312 μg/24 h
VAM 38.0 1.6 2.1 < 8 mg/24 h
Calcitonin 3,768.0 2,230.0 5,051.0 0–10 pg/ml
CEA 25.7 17.5 34.8 < 5 ng/ml
Cortisol 28.6 1.4 3.4 5–25 μg/dl
ACTH 56.6 124.0 283.0 5–46 pg/ml
VAM — vanillyl mandelic acid; CEA — carcinoembrionic antigen
large foci of pathologic MIBG concentration located in 
left and right epigastrium (Figure 4). Octreoscan scin-
tigraphy was also performed, detecting two foci with 
enhanced somatostatin receptor expression above the 
left kidney and in front of the right kidney. This loca-
tion corresponded to the findings of the I-131-MIBG 
scintigraphy (Figure 5). After preoperative treatment 
with alpha- and beta-blockers, and while still awaiting 
the result of histopathologic examination of thyroid le-
sions, the patient was qualified for surgical removal of 
bilateral lesions in adrenal glands.
The surgery was performed at the Department of 
General and Transplantation Surgery, Westpomeranian 
Provincial Hospital in Szczecin and both lesions were 
removed. During surgery, there were considerable fluc-
tuations in the patient’s blood pressure, ranging from 
50 to 260 mm Hg. After surgery, normal levels of metane-
phrines were observed, while chromogranin A levels 
decreased, although they were still beyond normal 
values (Table I). Histopathologic findings confirmed 
the presence of tissues corresponding to pheochro-
mocytoma in both tumours, without cytologic signs of 
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malignancy. Infiltration of either the capsule or blood 
vessels was not found. The mitotic index was 1/50 hpf, 
MIB-1 positive in 2% of cells.
Two months after the removal of pheochromocytomas, 
in May 2010, the patient was referred to the Department 
of Plastic and Endocrine Surgery for complete resec-
tion of thyroid together with left and right cervical, 
paralaryngeal and upper mediastinal lymph nodes.
Calcitonin levels fell from 3768 at the first diagnosis to 
2230 pg/ml after removal of pheochromocytoma. In July 
Figure 4. Foci with pathologic MIBG concentration in left and right epigastrium corresponding to adrenal tumours in a 
patient with MEN 2B
Rycina 4. Ogniska patologicznego gromadzenia MIBG w nadbrzuszu lewym oraz nadbrzuszu prawym, odpowiadające guzom 
nadnerczy u pacjenta z zespołem MEN 2B
Figure 2. Foci of medullary thyroid carcinoma in the right (A) and left (B) thyroid lobe in a patient with MEN 2B
Rycina 2. Ogniska raka rdzeniastego tarczycy w prawym (A) i lewym (B) płacie tarczycy u pacjenta z zespołem MEN 2B
A B
Figure 3. Enlarged lymph nodes with altered echostructure on the right (A) and left (B) in a patient with MEN 2B
Rycina 3. Powiększone, o zmienionej echo strukturze węzły chłonne po stronie prawej (A) i lewej (B) u pacjenta z zespołem 
MEN 2B
A B
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2010, after thyreidectomy calcitonin levels raised to 
5051 pg/ml which was the evidence for the persistence 
of medullary cancer. The 68Ga-DOTATATE PET/CTwas 
performed which did not find evident foci that might 
correspond to neoplastic process with somatostatin 
receptor expression, the patient was qualified for reop-
eration — bilateral cervical lymphadenectomy (October 
2010). After thyroid surgery, replacement therapy with 
L-thyroxin as well calcium and vitamin D3 treatment 
were started due to hypoparathyroidism. Medullary 
cancer metastases were found in one out of 18 lymph 
nodes on the left and in 12 out of 16 lymph nodes on 
the right; there was also infiltration of fat tissue around 
the lymph nodes. Between October 2010 and April 
2011, calcitonin levels ranged from 4,550 pg/ml to 5,545 
pg/ml and in the absence of alternative treatment, the 
patient was subject to radiotherapy. In March and April 
2011, the patient reported to the Cancer Centre and 
Institute of Oncology in Gliwice where he received 
adjuvant radiotherapy of lymph nodes of the neck and 
upper mediastinum at a fractional dose of 2.0 Gy up to 
a total dose of 60.0 Gy. At present, the patient’s condi-
tion is stable. He remains on replacement therapy with 
euthyrox, hydrocortisone, cortinef, calperos as well as 
alfadiol and biosterone.
Discussion
MEN 2 was first described in 1961 [5]. Since then, 
detailed descriptions of clinical syndromes associated 
with MEN 2 have followed; they are summarised in 
Table II [8]. MEN 2B is much less common than MEN 
2A, and although its clinical signs have been described 
on many occasions and are highly characteristic, its 
diagnosis is still too late, except for cases of familial 
MEN 2B occurrence. Our patient has had clinical 
symptoms of MEN 2B since the day he was born: i.e. 
congenital defects of the feet and marfanoid body ha-
bitus. Diarrhoea, which started as early as the second 
year of life and continues today, was probably asso-
ciated with calcitonin secretion, first by the foci of C 
cell hyperplasia, and then by medullary cancer. It has 
been reported that children with familial medullary 
thyroid carcinoma, MEN 2 and RET protooncogene 
mutation demonstrate hyperplasia of thyroid C cells 
and metastases by the age of five [9]. Unilateral foci 
Table II. Clinical syndromes associated with MEN 2
Tabela II. Zespoły kliniczne związane z zespołem MEN 2
Syndrome manifestation Percentage (%)
Multiple endocrine neoplasia type 2A (MEN 2A)
Medullary thyroid carcinoma 100
Pheochromocytoma 50
Hyperparathyroidism 10–20
MEN 2A variants
Familial medullary thyroid carcinoma (FMTC)
MEN 2A with cutaneous lichen amyloidosis (MEN 2A/CLA)
MEN 2A with Hirschsprung disease
Multiple endocrine neoplasia type 2B (MEN 2B)
Medullary thyroid carcinoma 100
Pheochromocytoma 50
Parathyroid disease 0
Marfanoid attributes > 90
Intestinal ganglioneuromatosis and mucosal 
neuromas
> 90
Figure 5. Foci with increased expression of somatostatin receptors above the left kidney and in front of the right kidney 
in octreoscan scintigraphy in a patient with MEN 2B
Rycina 5. Ogniska o wzmożonej ekspresji receptorów somatostatynowych nad nerką lewą oraz do przodu od nerki prawej 
w scyntygrafii receptorowej — octreoscan u pacjenta z zespołem MEN 2B
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of medullary thyroid carcinoma with the diameter of 
2 mm have been described in a 17 month-old patient 
[4] and children from families with MEN 2B have had 
medullary thyroid cancer metastases in their third year 
of life [10]. Skinder et al. and Gill et al. have also de-
scribed microfoci of medullary carcinoma in children 
occurring as early as the first year of life [5, 11]. Jasin 
et al. were the first to describe a family with MEN 2B 
[12]. The mother had medullary thyroid carcinoma, 
bilateral pheochromocytoma and such phenotypic 
features as mucosal neuromas and marfanoid body 
type. The oldest of her three children, a five year-old 
son,  had mucosal neuromas of the oral cavity and 
tongue as well as thyroid nodules and cervical lym-
phadenopathy. Calcitonin levels were at the limit 
of normal — 7.6 pg/mL, with age-adjusted normal 
range being < 8.4 pg/mL. Other biochemical markers 
i.e. chromogranin A, CEA, metanephrines, PTH and 
calcium, remained within normal ranges. His younger 
siblings, three year-old female twins, did not present 
phenotypic features of MEN 2B, no lesions were found 
in ultrasound examination of the thyroid, and enlarge-
ment of the lymph nodes was not observed. Calcitonin 
levels were 7.7 and 11.6 pg/mL, with the normal range 
being < 15 pg/mL. 
One year later, calcitonin levels in the boy were 
normal while they had increased to 9.4 and 13.9 pg/mL 
respectively in the twins, but still no lesions were ob-
served in ultrasound examination of the thyroid. Pro-
phylactic removal of the thyroid in the siblings is being 
considered. This family had RET protooncogene muta-
tion in exon 15, RET A883F. MEN 2B is associated with 
mutation at codons 883, 918 and 922, which represent 
3–5% of mutations within the RET protooncogene [8]. 
It is believed that medullary carcinoma in patients with 
the RET protooncogene mutation at codon 918 is more 
aggressive, which is also reflected in the clinical picture 
of MEN 2B in our patient — genetic tests showed de 
novo  M918T mutation in exon 16, which was not found 
in other family members [13]. Very similar cases have 
been described by Camacho et al. [14]. Their patients 
(two males and two females) demonstrated phenotypic 
features of MEN 2B such as neuromas of mucosa and 
tongue, osteoarticular disorders and corneal nerve 
thickening. Additionally, two patients showed marfa-
noid body habitus. Among these patients, the case of 
a 23 year-old man is similar to the one presented by our 
team. The only difference is that pheochromocytoma 
in the other adrenal gland developed two years after 
the diagnosis had been established. Both our patient 
and the four patients mentioned above suffered from 
constipation during infancy. This is related to intestinal 
ganglioneuromatosis. There are reports of severe con-
stipation in MEN 2B patients as early as the first year 
of life [15–17]. 
Full-blown MEN 2B with mucosal neuromas, pheo-
chromocytoma and medullary thyroid carcinoma occurs 
in only 50% of cases and when the diagnosis is based 
on these symptoms it is too late to introduce preventa-
tive measures. It seems advisable that all patients with 
mucosal neuromas and intestinal ganglioneuromatosis 
should undergo screening for MEN 2B. Only then 
would it be possible to start MEN 2B prophylaxis, even 
if it is not familial occurrence of the disease.
In summary, despite characteristic clinical features, 
the diagnosis of MEN 2B comes too late, which greatly 
worsens the prognosis in these patients.
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